MannKind (MNKD) Posts Q4 Loss of 66c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
RBC Keeps MannKind (MNKD) at 'Underperform'; Afrezza Plans in Limbo Until CCO Hired
March 15, 2016 6:45 AM EDTRBC Capital reaffirms MannKind (Nasdaq: MNKD) at Underperform with a price target of $0.15 following Q4 results and update issued Monday night.
ANalyst Adnan Butt commented, While MNKD has an approved diabetes drug in its hands in Afrezza and technosphere platform could have value in future drug development, we would like to see execution on four fronts before... More
MannKind (MNKD) Appoints New Chief Commercial Officer; COO Martens Resigns
March 14, 2016 4:01 PM EDTMannKind Corporation (Nasdaq: MNKD) announced that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts for Afrezza®, reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKinds executive leadership team.
Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global... More
MannKind (MNKD) Shares Jump 17%
March 14, 2016 9:48 AM EDTMannKind (NASDAQ: MNKD) stock spiked 17% Monday morning.
